Novocure Ltd NVCR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/26/24 EDT
12.55quote price arrow down-0.08 (-0.67%)
Volume
17,910
Close
12.63quote price arrow up+0.40 (+3.31%)
Volume
743,998
52 week range
10.87 - 83.60
Loading...
  • Open12.15
  • Day High12.65
  • Day Low12.01
  • Prev Close12.23
  • 52 Week High83.60
  • 52 Week High Date05/16/23
  • 52 Week Low10.87
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap1.353B
  • Shares Out107.09M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.49
  • YTD % Change-15.37

KEY STATS

  • Open12.15
  • Day High12.65
  • Day Low12.01
  • Prev Close12.23
  • 52 Week High83.60
  • 52 Week High Date05/16/23
  • 52 Week Low10.87
  • 52 Week Low Date11/13/23
  • Market Cap1.353B
  • Shares Out107.09M
  • 10 Day Average Volume1.07M
  • Dividend-
  • Dividend Yield-
  • Beta0.49
  • YTD % Change-15.37

RATIOS/PROFITABILITY

  • EPS (TTM)-1.95
  • P/E (TTM)-6.49
  • Fwd P/E (NTM)-7.17
  • EBITDA (TTM)-221.891M
  • ROE (TTM)-51.52%
  • Revenue (TTM)509.338M
  • Gross Margin (TTM)74.81%
  • Net Margin (TTM)-40.65%
  • Debt To Equity (MRQ)156.92%

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Novocure Ltd

 

Profile

MORE
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields...
William Doyle
Executive Chairman of the Board
Asaf Danziger
President, Chief Executive Officer, Director
Wilhelmus Groenhuysen
Chief Operating Officer
Ashley Cordova
Chief Financial Officer
Frank Leonard
Executive Vice President and President - Novocure Oncology
Barak Ben-Arye
General Counsel
Address
No. 4 The Forum, Grenville Street
Saint Helier
JE2 4UF
Jersey

Top Peers

SYMBOLLASTCHG%CHG
VCYT
Veracyte Inc
19.31-0.17-0.87%
GH
Guardant Health Inc
17.35+0.19+1.11%
CPRX
Catalyst Pharmaceuticals Inc
14.89+0.21+1.43%
KNSA
Kiniksa Pharmaceuticals Ltd
17.88+0.27+1.53%
ZLAB
Zai Lab Ltd
15.91+0.17+1.08%